Personalis, Inc. stock is up 47.17% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 December’s closed higher than November. 100% of analysts rate it a buy.
Personalis, Inc. operates as a cancer genomics company worldwide. It provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection.